6938.HK
RIBOLIFE-B
HK$68.50
+1.93%
2026-02-27
About RIBOLIFE-B
Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercho lesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases; and RBD1119 for treating thrombotic diseases that is in Phase I clinical trial. The company also develops SR122 and SR126 for treating dyslipidemia; RBD3103 for treating renal diseases; RBD6096 for the treatment of thrombotic diseases; SR118 for treating metabolic diseases; RBD1016, which is in Phase II clinical trial for the treatment of CHB and CHD; RBD3133 for treating weight loss; RBD8088 for treating glioma; SR131 for treating CNS diseases; and SR111, SR112, and SR113 for the treatment of metabolic dysfunction-associated steatohepatitis. Suzhou Ribo Life Science Co., Ltd. was incorporated in 2007 and is based in Kunshan, China.
Key Fundamentals
Forward P/E
-0.36
EPS (TTM)
HK$-1.98
Revenue Growth (YoY)
-41.4%
Profit Margin
-187.2%
Debt/Equity
2054.49
Market Cap
HK$9.93B
Avg Volume (10D)
148K
Recent Breakout Signals
No recent breakout signals detected for 6938.HK.
Recent Price Range (60 Days)
60D High
HK$95.80
60D Low
HK$58.55
Avg Volume
987K
Latest Close
HK$68.50
Get breakout alerts for 6938.HK
Sign up for Breakout Scanner to receive daily notifications when 6938.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
RIBOLIFE-B (6938.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 6938.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 6938.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.